XAIR

Beyond Air, Inc. [XAIR] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

XAIR Stock Summary

Top 10 Correlated ETFs

XAIR


Top 10 Correlated Stocks

XAIR


In the News

01:01 28 Mar 2024 XAIR

Beyond Air (XAIR) Upgraded to Buy: What Does It Mean for the Stock?

Beyond Air (XAIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

02:37 28 Mar 2024 XAIR

Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript

Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript

06:26 28 Mar 2024 XAIR

Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.43 per share a year ago.

07:07 28 Mar 2024 XAIR

Beyond Air, Inc. (XAIR) Q2 2024 Earnings Call Transcript

Beyond Air, Inc. (NASDAQ:XAIR ) Q2 2024 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Jeremy Jacoby - Truist Securities Marie Thibault - BTIG Matt Kaplan - Ladenburg Thalmann Operator Good afternoon and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter ended September 30, 2023. At this time, participants are in a listen-only mode.

04:05 28 Mar 2024 XAIR

Beyond Air® Schedules Second Fiscal Quarter 2024 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.

07:30 28 Mar 2024 XAIR

Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two proffered posters at the upcoming American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics 2023, which is scheduled to be held October 11th – 15th in Boston, Massachusetts. Abstracts are scheduled to be released to AACR-NCI-EORTC registrants today 12:00 pm U.S. ET.

10:01 28 Mar 2024 XAIR

3 Top Penny Stocks To Buy Now According To Insiders In August

The realm of penny stocks, often characterized by their affordable price tag, has become a hotspot for investors eager to seize the stock market's opportunities. These stocks, typically valued under $5, carry inherent risks and promise impressive rewards.

08:17 28 Mar 2024 XAIR

Beyond Air, Inc. (XAIR) Q1 2024 Earnings Call Transcript

Beyond Air, Inc. (NASDAQ:XAIR ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities Marie Thibault - BTIG Scott Henry - ROTH Capital Jason Bednar - Piper Sandler Matt Kaplan - Ladenburg Thalmann Yale Jen - Laidlaw & Company Operator Good afternoon and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter ended June 30, 2023. At this time, all participants are in a listen-only mode.

07:46 28 Mar 2024 XAIR

Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.37 per share a year ago.

04:05 28 Mar 2024 XAIR

Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast

GARDEN CITY, N.Y., July 24, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.

XAIR Financial details

Company Rating
Neutral
Market Cap
56.94M
Income
-63.23M
Revenue
298K
Book val./share
0.81
Cash/share
1.22
Dividend
-
Dividend %
-
Employees
98
Optionable
No
Shortable
Yes
Earnings
20 Jun 2024
P/E
-0.79
Forward P/E
-0.95
PEG
0.14
P/S
108.87
P/B
2.15
P/C
1.42
P/FCF
-1.04
Quick Ratio
3.14
Current Ratio
3.78
Debt / Equity
0.65
LT Debt / Equity
0.56
-
-
EPS (TTM)
-0.73
EPS next Y
-1.82
EPS next Q
-0.49
EPS this Y
10.71%
EPS next Y
149.32%
EPS next 5Y
116.89%
EPS last 5Y
19.29%
Revenue last 5Y
-100%
Revenue Q/Q
305.08%
EPS Q/Q
13.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
26.32%
Inst Trans
0.82%
ROA
-121%
ROE
-187%
ROC
-1.34%
Gross Margin
-117%
Oper. Margin
-11909%
Profit Margin
-13727%
Payout
-
Shs Outstand
36.04M
Shs Float
27.78M
-
-
-
-
Target Price
-
52W Range
1.17-7.16
52W High
-75.29%
52W Low
+73%
RSI
53
Rel Volume
0.24
Avg Volume
363.96K
Volume
86.15K
Perf Week
12.34%
Perf Month
-15.61%
Perf Quarter
-28.51%
Perf Half Y
-32.68%
-
-
-
-
Beta
-0.17
-
-
Volatility
0.06%, 0.16%
Prev Close
-0.57%
Price
1.73
Change
2.37%

XAIR Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-03-31

Metric History 2019-03-312020-03-312021-03-312022-03-31 2023-03-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.910.120.0500
Net income per share
-0.77-1.73-1.27-1.68-1.86
Operating cash flow per share
0.16-1.33-1.09-0.9-1.1
Free cash flow per share
0.15-1.33-1.14-0.96-1.23
Cash per share
0.931.721.923.131.53
Book value per share
0.471.571.692.831.26
Tangible book value per share
0.421.541.672.981.35
Share holders equity per share
0.471.571.692.831.26
Interest debt per share
0.030.430.420.170.12
Market cap
39.94M92.05M99.03M171.46M202.32M
Enterprise value
38.87M77.1M71.33M94.71M176.76M
P/E ratio
-6.09-4.62-4.33-3.97-3.62
Price to sales ratio
5.1766.22113.4300
POCF ratio
29.78-6.04-5.04-7.41-6.13
PFCF ratio
31.09-6.02-4.82-6.97-5.49
P/B Ratio
9.925.093.252.365.34
PTB ratio
9.925.093.252.365.34
EV to sales
5.0355.4681.7100
Enterprise value over EBITDA
-12.97-4.29-3.24-3.2-3.47
EV to operating cash flow
28.98-5.06-3.63-4.09-5.35
EV to free cash flow
30.26-5.04-3.47-3.85-4.79
Earnings yield
-0.16-0.22-0.23-0.25-0.28
Free cash flow yield
0.03-0.17-0.21-0.14-0.18
Debt to equity
0.070.270.230.050.09
Debt to assets
0.030.180.170.040.05
Net debt to EBITDA
0.360.831.262.590.5
Current ratio
1.615.469.88.683
Interest coverage
-2.03K-593.98-34.6-52.53-1.72K
Income quality
-0.20.760.860.530.56
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.896.3911.9900
Research and developement to revenue
0.517.6614.4500
Intangibles to total assets
0.050.020.010.020.02
Capex to operating cash flow
-0.0400.050.060.12
Capex to revenue
-0.01-0.03-1.0200
Capex to depreciation
-0.87-0.27-4.22-2.46-3.31
Stock based compensation to revenue
0.312.575.6100
Graham number
2.877.836.9510.357.28
ROIC
-0.71-0.78-0.58-0.52-1.1
Return on tangible assets
-0.73-0.74-0.57-0.44-0.83
Graham Net
0.331.21.442.330.67
Working capital
3.29M21.74M33.42M82.23M39.63M
Tangible asset value
3.53M17.68M30.09M76.37M40.4M
Net current asset value
3.29M17.27M27.16M71.96M32.69M
Invested capital
0.070.270.230.050.09
Average receivables
23.94K86.01K295.06K535K627.5K
Average payables
1M1.71M1.79M1.23M1.57M
Average inventory
319.47K3.58M4.2M1.12M739.5K
Days sales outstanding
2.2632.59194.8300
Days payables outstanding
00001.33K
Days of inventory on hand
0000742.5
Receivables turnover
161.2911.21.8700
Payables turnover
00000.28
Inventory turnover
00000.49
ROE
-1.63-1.1-0.75-0.59-1.47
Capex per share
-0.010-0.05-0.06-0.13

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q2

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000.01
Net income per share
-0.4-0.43-0.66-0.45-0.51
Operating cash flow per share
-0.31-0.28-0.28-0.55-0.45
Free cash flow per share
-0.34-0.31-0.34-0.57-0.5
Cash per share
2.091.781.51.821.22
Book value per share
1.971.71.241.130.81
Tangible book value per share
2.071.81.321.20.86
Share holders equity per share
1.971.71.241.130.81
Interest debt per share
0.10.10.110.540.56
Market cap
222.45M194.19M207.08M133.69M73.46M
Enterprise value
195.57M171.54M181.51M119.2M77.08M
P/E ratio
-4.65-3.81-2.57-2.37-1.13
Price to sales ratio
0002.27K307.36
POCF ratio
-24.13-22.82-24.54-7.79-5.13
PFCF ratio
-21.85-21.24-19.79-7.45-4.59
P/B Ratio
3.783.815.463.772.85
PTB ratio
3.783.815.463.772.85
EV to sales
0002.02K322.5
Enterprise value over EBITDA
-15.9-12.77-13-7.69-4.53
EV to operating cash flow
-21.21-20.16-21.51-6.95-5.38
EV to free cash flow
-19.21-18.76-17.35-6.64-4.82
Earnings yield
-0.05-0.07-0.1-0.11-0.22
Free cash flow yield
-0.05-0.05-0.05-0.13-0.22
Debt to equity
0.050.060.090.480.65
Debt to assets
0.040.040.050.230.29
Net debt to EBITDA
2.191.691.830.94-0.21
Current ratio
6.475.6935.273.78
Interest coverage
-262.94-304.57119.95-100.47-19.18
Income quality
0.720.620.41.140.82
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000185.3642.72
Research and developement to revenue
00079.5829.83
Intangibles to total assets
0.020.020.020.020.03
Capex to operating cash flow
0.10.070.240.050.12
Capex to revenue
000-13.47-7.04
Capex to depreciation
-4.08-1.79-5.95-1.76-3.31
Stock based compensation to revenue
000103.6427.03
Graham number
4.214.044.283.383.05
ROIC
-0.19-0.23-0.28-0.27-0.38
Return on tangible assets
-0.15-0.18-0.3-0.2-0.29
Graham Net
1.51.190.660.770.33
Working capital
63.48M54.42M39.63M51.35M34.68M
Tangible asset value
61.92M53.76M40.4M37.56M27.3M
Net current asset value
56.69M47.5M32.69M29.46M17.96M
Invested capital
0.050.060.090.480.65
Average receivables
514K495.5K614K666.5K555K
Average payables
1.52M1.71M1.71M1.88M2.52M
Average inventory
698.5K833K1.04M1.23M1.46M
Days sales outstanding
0001.04K161.17
Days payables outstanding
1.01K1.87K589.09516.24685.83
Days of inventory on hand
357.491.26K329.9397.72327.92
Receivables turnover
0000.090.56
Payables turnover
0.090.050.150.170.13
Inventory turnover
0.250.070.270.230.27
ROE
-0.2-0.25-0.53-0.4-0.63
Capex per share
-0.03-0.02-0.07-0.03-0.05

XAIR Frequently Asked Questions

What is Beyond Air, Inc. stock symbol ?

Beyond Air, Inc. is a US stock , located in Garden city of Ny and trading under the symbol XAIR

What is Beyond Air, Inc. stock quote today ?

Beyond Air, Inc. stock price is $1.73 today.

Is Beyond Air, Inc. stock public?

Yes, Beyond Air, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap